Idhifa (enasidenib) — Highmark
Relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation
Initial criteria
- age ≥ 18 years
- Diagnosis of relapsed or refractory acute myeloid leukemia (AML, ICD-10: C92.5)
- Member is isocitrate dehydrogenase-2 (IDH2) mutation-positive as detected by an FDA-approved test
Reauthorization criteria
- Prescriber attests that the member is tolerating therapy
- Member has experienced a therapeutic response defined as one (1) of the following:
- Disease improvement OR delayed disease progression
Approval duration
12 months